Two approaches for using observational data to emulate clinical trials are presented in a Research and Reporting Methods article. “Addressing the issues discussed in this
Molnupiravir use within 5 days of a positive SARS-CoV-2 test was associated with a reduction of postacute sequelae of SARS-CoV-2 (PASC) in a large VA
The need for new therapies and adaptations in treating severe asthma with SARS-CoV-2 circulating and COVID-19 a common respiratory illness are discussed in a review
The immunomodulatory “off-target” effects of bacille Calmette–Guérin Denmark (BCG-Denmark) vaccine did not lower the risk of COVID-19 in health care workers in a placebo-controlled, international, double-blind
The COVID-19 Treatment Guidelines Panel last week updated its COVID-19 treatment guidelines, adding sections on pregnancy and lactation, revising information on therapeutic management of nonhospitalized
In the phase 2b portion of a phase 2/3 clinical study, 5 days of the once-daily, novel, oral SARS-CoV-2 3C-like protease inhibitor ensitrelvir fumaric acid
Following FDA regulatory action (see Wednesday’s PNN), CDC has taken steps to simplify COVID-19 vaccine recommendations and allow more flexibility for people at higher risk
At 12 clinical sites in Brazil, ambulatory patients with early COVID-19 at high risk of progression to severe disease requiring advanced care responded positively to
Among nonhospitalized adults with mild-to-moderate SARS-CoV-2 infection at high risk for progression to severe disease, treatment with the recombinant human immunoglobulin G1 monoclonal antibodies amubarvimab
The emerging SARS-CoV-2 subvariant XBB.1.16 may carry the previously rare symptom of conjunctivitis, according to a pediatrician in India and a news report in the